Atara Biotherapeutics
ATRA
115 hedge funds and large institutions have $1.92B invested in Atara Biotherapeutics in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 26 reducing their positions, and 22 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 26
12% more capital invested
Capital invested by funds: $1.71B → $1.92B (+$209M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.14% less ownership
Funds ownership: 4.23% → 4.09% (-0.14%)
7% less funds holding
Funds holding: 124 → 115 (-9)
29% less call options, than puts
Call options by funds: $3.53M | Put options by funds: $4.96M
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$12.4M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$9.72M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$9.65M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.49M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$6.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$11.6M |
| 3 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$6.95M |
| 4 |
Morgan Stanley
New York
|
-$5.94M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$5M |
ATRA Hedge Fund Activity: Q3 2018 in Review
115 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2018, worth a combined $1.92B — up 12% from $1.71B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ATRA and 13 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 42 added.
The largest buyer was JP Morgan Chase, adding an estimated $12.4M. The largest seller was Fidelity Investments, cutting an estimated $37.3M.
- 115 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2018, down from 124 in Q2 2018.
- Funds reported $1.92B of Atara Biotherapeutics stock for Q3 2018, up 12% quarter-over-quarter.
- 13 funds opened new Atara Biotherapeutics positions in Q3 2018 and 22 closed out, a net change of -9 holders.
- The largest Atara Biotherapeutics buyer in Q3 2018 was JP Morgan Chase, an estimated $12.4M added.
- The largest Atara Biotherapeutics seller in Q3 2018 was Fidelity Investments, an estimated $37.3M sold.
Based on aggregated 13F filings for Q3 2018.